5 Things to Know is CNBC's Morning Squawk newsletter, a before-the-bell briefing on the most important news, trends and analysis that investors need to start their trading day. Subscribe here to ...

Replimune gets third chance at US approval for skin cancer drug Replimune said on Friday it plans to apply a third time for approval of its experimental skin cancer drug in the coming days after ...